fbpx
CAS Insight

molecules of the month

Genentech ER Degrader

selective ER degrader (SERD) + full antag.

oral (30 mg QD), Ph. III for ER+, HER2- BC

from profiling >4k cmpds for desired MoA

giredestrant (GDC-9545)

Genentech, South San Francisco, CA

GDC-9545 giredestrant SERD Genentech structure Drug Hunter Molecules of the Year
1 min read

The Genentech next generation oral SERD (selective estrogen receptor degrader) and full antagonist, giredestrant (GDC-9545), is a potential best-in-class Ph. III candidate for ER+, HER2- breast cancer (NCT04546009). It is the third SERD clinical candidate from Genentech (after GDC-0810 and GDC-0927) and a number of oral SERDs have previously been highlighted on Drug Hunter (including SAR439659, AZD9833, GNE-149). The oral, once-daily molecule has been well-tolerated at doses up to 250 mg and a standardized 30 mg dose has been selected for development. Interim analysis and updated data from trials NCT03916744 and NCT03332797 show promising activity including in the presence of ESR1 mutations. Hormone therapy is a mainstay of treatment for breast cancer, but side effects have a significant quality of…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: